Pfizer's Quarterly Earnings Preview: What You Need to Know

Core Viewpoint - Pfizer Inc. is set to announce its fiscal fourth-quarter earnings for 2025, with expectations of a decline in profit per share compared to the previous year [1][2]. Financial Performance - Analysts predict Pfizer will report a profit of $0.56 per share on a diluted basis, which is an 11.1% decrease from $0.63 per share in the same quarter last year [2]. - For the full year, the expected EPS is $3.11, remaining unchanged from the previous year, but a decline of 4.8% to $2.96 is anticipated for fiscal 2026 [3]. Stock Performance - Pfizer's stock has underperformed the S&P 500 Index, which gained 16.2% over the past 52 weeks, with Pfizer shares down 5.3% during the same period [4]. - The stock also lagged behind the Health Care Select Sector SPDR Fund, which returned 11.6% [4]. Market Concerns - The underperformance of Pfizer's stock is attributed to concerns over patent expirations for key medications such as Eliquis and Ibrance, as well as declining sales from COVID-19 products [5]. Recent Earnings Report - On November 4, 2025, Pfizer reported its Q3 results, with an adjusted EPS of $0.87, surpassing Wall Street's expectation of $0.66. The company's revenue was $16.7 billion, exceeding forecasts of $16.6 billion [6]. Analyst Ratings - The consensus opinion on Pfizer stock is moderately bullish, with a "Moderate Buy" rating. Among 24 analysts, six recommend a "Strong Buy," one a "Moderate Buy," 16 a "Hold," and one a "Strong Sell." The average price target is $27.95, suggesting an 11% potential upside from current levels [7].